Oncimmune Holdings plc
("Oncimmune" or the
"Company")
Results of General Meeting and
Total Voting Rights
Oncimmune Holdings plc (AIM: ONC.L),
a leading autoantibody profiling company providing research
services to the pharmaceutical and biotechnology industry to enable
the delivery of precision medicine is pleased to announce that, at
the General Meeting held earlier today, all the Resolutions were
duly passed.
The full text of the Resolutions can
be found in the Notice of General Meeting, which is contained in
the Circular published and issued to shareholders on 23 October
2024 and is available on the Company's website at:
www.oncimmune.com
The Company is pleased to confirm
that as a result of obtaining shareholder approval for the
resolutions required to implement the Fundraising, , the Company
has raised total gross proceeds of approximately £2.3 million in
aggregate from the Fundraising.
5,500,000 Firm Placing Shares and
500,000 Firm Subscription Shares were admitted to trading on AIM on
23 October 2024 on First Admission. Application has been made to
the London Stock Exchange for the admission of a total of
31,631,072 new Ordinary Shares to trading on AIM pursuant to the
Second Admission. Second Admission comprises (i) 6,500,000
Conditional Placing Shares; (ii) 1,833,333 Conditional Subscription
Shares (iii) 22,351,003 Conversion Shares
and (iv) 946,736 Retail Offer Shares. These new Ordinary Shares
will rank pari passu with the Existing Ordinary Shares. Admission
of the Conditional Placing Shares, Conditional Subscription Shares,
Conversion Shares and Retail Offer Shares is expected to occur at
8:00 a.m. on 11 November 2024.
Total Voting Rights
Following Second Admission, the
Company will have 111,773,219 Ordinary Shares in issue and there
are no shares held in treasury. This figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.
This announcement should be read in
conjunction with the full text of the Circular posted to
Shareholders on 23 October 2024. Unless otherwise defined, all
capitalised terms used but not defined in this announcement shall
have the meaning given to them in the announcement of the
Fundraising made by the Company on 18 October 2024.
For
further information:
Oncimmune Holdings plc
contact@oncimmune.com
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
Geoff Nash, Callum Davidson, Trisyia
Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist
Sales)
Ondraya Swanson (ECM)
+44 (0) 20 7220 0500
Zeus (Joint Broker)
Dominic King, Dan Bate
+44 (0)20 3829 5000